Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis

Author:

Kanie Takayoshi1,Mizuno Atsushi1234,Takaoka Yoshimitsu1,Suzuki Takahiro1,Yoneoka Daisuke5,Nishikawa Yuri67,Tam Wilson Wai San8,Morze Jakub9,Rynkiewicz Andrzej10,Xin Yiqiao11,Wu Olivia11,Providencia Rui12,Kwong Joey SW13

Affiliation:

1. Department of Cardiology; St. Luke's International Hospital; Tokyo Japan

2. Penn Medicine Nudge Unit; University of Pennsylvania Philadelphia; Philadelphia PA USA

3. Leonard Davis Institute for Health Economics; University of Pennsylvania; Philadelphia PA USA

4. Division of Cardiovascular Medicine; Hospital of the University of Pennsylvania; Philadelphia PA USA

5. Division of Biostatistics and Bioinformatics, Graduate School of Public Health; St. Luke’s International University; Tokyo Japan

6. Department of Gerontological Nursing and Healthcare Systems Management, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan

7. Department of Gerontological Nursing; Kyorin University; Tokyo Japan

8. Alice Lee Center for Nursing Studies; NUS Yong Loo Lin School of Medicine; Singapore Singapore

9. Department of Human Nutrition; University of Warmia and Mazury; Olsztyn Poland

10. Department of Cardiology and Cardiosurgery; School of Medicine, University of Warmia and Mazury; Olsztyn Poland

11. Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing; University of Glasgow; Glasgow UK

12. Barts Heart Centre; St Bartholomew's Hospital, Barts Health NHS Trust; London UK

13. Global Health Nursing, Graduate School of Nursing Science; St. Luke's International University; Tokyo Japan

Publisher

Wiley

Subject

Pharmacology (medical)

Reference459 articles.

1. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure;Arturi;Endocrine,2017

2. Sotagliflozin In patients with diabetes and recent worsening heart failure;Bhatt;New England Journal of Medicine,2021

3. Effect of sotagliflozin on cardiovascular events in patients with type 2 diabetes post worsening heart failure (SOLOIST-WHF trial) Available from clinicaltrials.gov/ct2/show/NCT03521934

4. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV);Cannon;American Heart Journal,2018

5. Design and baseline characteristics of the evaluation of ertuglifozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV);Cannon;Journals of the American College of Cardiology,2018

Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3